Rezolute (NASDAQ:RZLT) vs. 2seventy bio (NASDAQ:TSVT) Head to Head Analysis

Rezolute (NASDAQ:RZLT) and 2seventy bio (NASDAQ:TSVT) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, earnings, analyst recommendations, dividends and profitability.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Rezolute and 2seventy bio, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rezolute	0	0	7	0	3.00
2seventy bio	1	4	4	1	2.50

Rezolute presently has a consensus target price of $10.43, suggesting a potential upside of 142.52%. 2seventy bio has a consensus target price of $11.43, suggesting a potential upside of 184.29%. Given 2seventy bio’s higher probable upside, analysts plainly believe 2seventy bio is more favorable than Rezolute.

Profitability

This table compares Rezolute and 2seventy bio’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Rezolute	N/A	-60.90%	-54.58%
2seventy bio	-313.51%	-67.59%	-31.71%

Valuation and Earnings

This table compares Rezolute and 2seventy bio’s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rezolute	N/A	N/A	-$51.79 million	($1.14)	-3.77
2seventy bio	$71.20 million	2.90	-$217.57 million	($4.35)	-0.92

Rezolute has higher earnings, but lower revenue than 2seventy bio. Rezolute is trading at a lower price-to-earnings ratio than 2seventy bio, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Rezolute has a beta of 1.2, indicating that its share price is 20% more volatile than the S&P 500. Comparatively, 2seventy bio has a beta of 1.77, indicating that its share price is 77% more volatile than the S&P 500.

Insider & Institutional Ownership

83.0% of Rezolute shares are held by institutional investors. Comparatively, 93.9% of 2seventy bio shares are held by institutional investors. 20.8% of Rezolute shares are held by insiders. Comparatively, 7.2% of 2seventy bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

About Rezolute

Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

About 2seventy bio

2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.